NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

If you purchased or acquired securities in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your ...

PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...

Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) has earned an average rating of “Hold” from the nine ratings firms that are presently covering the stock, Marketbeat reports.

PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of ...

NEW YORK, Feb. 12, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Pacira (PCRX).

PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of ...

Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its ...